Background: Polymorphisms of angiotensin I converting enzyme (ACE) gene have been inconsistently associated with breast cancer risk. We examined these associations by performing a meta-analysis. Materials and methods: Four studies (cases: 1422; controls: 3044) testing the association between ACE insertion/deletion (I/D) polymorphism and breast cancer were examined. The analyses were performed using the Review Manager 5.0.25 software package.
Introduction
Angiotensin II, the main biologically active peptide of the renin-angiotensin system (RAS), plays an important role in blood pressure and cardiovascular homeostasis. Previous data indicated that angiotensin II contributed to cancer development and progression, through its effects on proliferation, angiogenesis and tumour metastasis. 1 The production of angiotensin II is regulated by angiotensin I converting enzyme (ACE). Previous studies have demonstrated that the interindividual difference in ACE levels is governed by genetic variation at the ACE locus. 2 It has been suggested that the incidence of breast cancer is much higher in subjects with the ACE DD genotype than others, 3 but published studies are inconsistent. [4] [5] [6] [7] To help clarify the inconsistent findings, we conducted a meta-analysis of published studies on ACE insertion/deletion (I/D) polymorphism and risk of breast cancer.
Methods
Observational studies published in English from January 1966 to June 2010 identified using PubMed software to search Medline (U.S. National Library of Medicine, Bethesda, MD) were considered in this meta-analysis. The following key words: (angiotensin-converting enzyme 
Assessment of study quality
The methodological quality of included studies was assessed with criteria as previously described. 8 Two investigators (Sun ML and Liu CY) independently reviewed the articles and extracted the data using a standard approach. Discrepancies were resolved through discussion. The studies included in the analysis should satisfy the following criteria: (1) assessment of ACE I/D polymorphism and breast cancer risk; (2) sufficient information upon genotype counts. Two studies were excluded for lack of information on genotype distribution.
Data extraction
For each study we abstracted the first author's last name, year of publication, ethnicity of participants, numbers of cases and controls, frequency of insertion or deletion genotypes. Hardy-Weinberg equilibrium was assessed using the χ 2 test.
Statistical methods
All the statistical analyses were performed by the Review Manager 5.0.25 package (The Cochrane Collaboration, Oxford, UK). In this meta-analysis, we used the randomeffects model to combine the individual effect-size estimates, because the fixed-effects model suggested between-study heterogeneity. 9 Publication bias was assessed using a funnel plot.
Results

Characteristics of the included studies
Nine studies examined the relationship between ACE gene insertion/deletion polymorphisms and breast cancer risk. [3] [4] [5] [6] [7] [10] [11] [12] [13] For the two overlapping studies from Turkey, 6,12 the one with smaller sample size was excluded. 12 Data from four studies, 4-7 including 1422 cases and 3044 controls, were available for the meta-analysis. One article 4 provided data on four separate study ethnicities. The design in two studies 6, 7 was hospital-based, and in the other two studies 4, 5 was population-based. Among them, the study conducted by Koh et al. 5 was a prospective observational study. All the included studies were in Hardy-Weinberg equilibrium. Clinical characteristics and genotype distribution of the eligible studies are demonstrated in tables 1 and 2.
Association of ACE I/D polymorphisms with breast cancer-estimation of pooled OR. As shown in figure 1A , compared with ACE ID/II genotype, patients with DD genotype showed a non-significant risk for breast cancer (OR 1.00; 95%CI 0.76 to 1.33; p = 0.98). In addition, compared with ID/DD genotype carriers, ACE homozygotes of II allele only conferred a non-significant 11% increased risk for breast cancer (OR 1.11; 95%CI 0.96 to 1.28; p = 0.14) (figure 1B).
To generate more information, we further assessed the risk for breast cancer between I/D genotype carriers and homozygotes (both DD and II genotypes), which also showed no significant association (OR 0.94; 95%CI 0.83 to 1.07; p = 0.38) ( figure 1C ).
Publication bias
The funnel plot based on the above studies, which is asymmetrical, indicates that publication bias may have existed in this meta-analysis (figure 2).
Discussion
To our best knowledge, the present study is the first metaanalysis to evaluate the association between ACE I/D variants and breast cancer risk. Overall, no significant association was observed between the ACE I/D polymorphisms and breast cancer risk.
ACE, the key enzyme to angiotensin II production, plays an important role in regulating the RAS activity. In pathological conditioning, such as hypertension, atherosclerosis and tumour, ACE is upregulated and the RAS is overactivated, which accelerates the disease progression. Evidence has suggested that angiotensin II plays an important role in promoting neovascularisation, cell proliferation and migration, and cell cycle regulation, and thus might contribute to tumour formation and progression. 1 ACE inhibitors are used widely as antihypertensive agents, and several studies suggest that users of ACE inhibitors exhibit a reduced risk of cancer, 14, 15 although the results are not consistent. 16 Recently, a meta-analysis suggested that angiotensin receptor blockers (ARBs) were associated with a modestly increased risk of new cancer diagnosis, 17 whereas another study refuted the above results. 18 Studies have demonstrated that plasma ACE levels are highly genetically determined. Homozygotes for the D allele display as high as two times the ACE levels compared with the homozygotes for the I allele, whereas the ID heterozygotes show an intermediate level. 2 This point encouraged us to clarify the association between ACE I/D variant and disease progression. We first examined the association between DD genotype and breast cancer risk, and no significant relationship was found. Considering the lower ACE activity in II homozygotes, we further compared the II homozygotes with ID/DD genotype carriers for breast cancer and the association was also not significant. Similar results were found between DD/II homozygotes and I/D carriers, which further convinced us that ACE I/D polymorphism might not be related to breast cancer risk.
However, the RAS is a complex physiological system involving multiple genes that define its activity and its regulatory action. Previous studies have demonstrated that other genes and polymorphisms also contribute to RAS activity. 19 Therefore, the effects of any single polymorphisms and/or any single gene in the RAS system might have very limited impact on breast cancer. Systematically screening polymorphisms of multiple genes in RAS system might be beneficial to interpret the association between gene polymorphisms and breast cancer.
Several potential limitations of the current study should be considered. First, heterogeneity among the referenced studies, resulting from different clinical characteristics, such as race, age at menarche and first live birth, family history of breast cancer, alcohol drinking and use of replacement hormone, may affect the analysis results. Two studies did not supply the above information. Some studies selected controls randomly from a healthy population, whereas other selected from hospital-based cancer-free patients. Another limitation may be the potential threat of publication bias. Considerable evidence indicates that trials with 'negative' results may have difficulty getting published compared with trials that find significant benefits. 20 According to the funnel plot constructed, publication bias is likely to exist. Third, the relationship between ACE I/D polymorphism and breast cancer risk was analysed without considering the gene-environment interactions. Although evidence supported that there was a significant interaction effect between green tea intake and ACE genotype on risk of breast cancer, 11 this study failed to draw a conclusion due to the insufficiency of environmental factors in these studies. In addition, the gene-gene interactions and breast cancer risk should be further investigated.
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